Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment.

Formed in 2013, we are headquartered at CIC Cambridge Campus, 1 Broadway, Cambridge, MA, USA and an ISO 9001:2015 laboratory in Bangalore, India.

Our key drivers to success include a platform approach to novel therapeutics, an experienced Antibody engineering team, global advisors and investors.

About us

Our Approach

“Combination of Zumutor’s platforms lead to novel and improved monoclonal antibody therapeutics”

Discover The Future

We attract, retain and nurture scientific talent who shares our dream of pushing the boundaries of therapeutic research and development.

Contact Us